Affimed NV (LTS:0HL9)
$ 6.1 -0.37 (-5.72%) Market Cap: 93.50 Mil Enterprise Value: 35.19 Mil PE Ratio: 0 PB Ratio: 1.46 GF Score: 50/100

Affimed NV at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 27, 2021 / 02:00PM GMT
Release Date Price: $61.9 (-4.48%)
Alethia Young
Cantor Fitzgerald - Analyst

Hey, everybody. It's Alethia Young here at Cantor. I cover large-cap, small and mid-cap biotech. Very happy to have Affimed, and I have Adi Hoess who is the CEO of the Company and will be doing a formal presentation for the whole 30 minutes. So with that, I will turn it over to Adi.

Adi Hoess
Affimed N.V. - CEO

Thank you, Alethia, and welcome, everybody. And yes, thanks for listening to my presentation about what Affimed does. As you can see by my title, we are indeed working on activating innate immunity, in particular, to treat cancer patients. We are doing this by the use of innate cell engagers. Now these are bispecific antibodies that on the one side, have the opportunity to attach to innate cells, which can be natural killer cells on macrophages and on the other side, attached to cancer cells. This approach indeed has the opportunity to elicit a full immune response as activation of the innate immune system is also a promising approach to activate the adaptive immune system.

Now why are we doing it? It

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot